American Heart Association (AHA)

The American Heart Association (AHA) funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke. The AHA also is a key resource for the latest cardiology science through its journals and annual meeting.

Bertram Pitt, MD, a professor of medicine emeritus at the University of Michigan School of Medicine, explains the role of sodium–glucose co-transporter-2 (SGLT-2) inhibitors for heart failure (HF). Initially developed to treat diabetes, these drugs have been shown to improve HF outcomes in HF in several large, randomized trials over the past few years, including SOLOIST-WHF, DAPA-HF, EMPEROR-Preserved, and the DELIVER trials. The positive results earned their inclusion in the 2022 AHA/ACC/HFSA Guideline for

What clinical research tells us about sotagliflozin and heart failure

Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.

AHA President Michelle Albert explains what can be done to boost healthcare equity and diversity in cardiology.

AHA President Michelle Albert on addressing health equity issues in cardiology

American Heart Association President Michelle Albert, MD, talked to us about about how to address health inequities in cardiology departments.

Ajay J. Kirtane, MD, director of the cardiac catheterization laboratories and professor of medicine at NewYork-Presbyterian/Columbia University Irving Medical Center, explains the current trial data on catheter renal denervation to treat drug-resistant hypertension at AHA 2022.

Where renal denervation stands for the treatment of drug-resistant hypertension

Ajay Kirtane, MD, director of the cardiac catheterization laboratories at NewYork-Presbyterian/Columbia University Irving Medical Center, explained the most recent clinical trial data on this topic. 

Surgeons Operating On Patient

AI model predicts risk of post-operative AFib

Post-operative atrial fibrillation was once viewed as a fairly insignificant issue, but more recent research suggests it can increase a patient’s risk of multiple adverse events. 

A key step forward: Researchers ID the genes responsible for CAD

The team hopes its findings can lead to significant progress in the war against fatty plaques.

Atrial Fibrillation and its location in the atrium detected using the Vektor arrhythmia detection software. COVID infection can cause the development of AFib, AF, in patients as a long-COVID symptom.

VIDEO: The link between COVID-19 and atrial fibrillation

Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital, discussed the cases of AFib being seen in long-COVID patients.

Nemours Children's Hospital pediatric cardiologists explain lessons learned about cardiac involvement and long-term issues from multisystem inflammatory syndrome in children (MIS-C), a rare but serious disease caused by exposure to the COVID-19 virus. #MIS-C #COVID #coronavirus #SARSCoV2

VIDEO: Cardiologists share the latest details on COVID-related MIS-C

In this new video, pediatric cardiologists discuss some of the long-term issues associated with multisystem inflammatory syndrome in children (MIS-C), a rare disease linked to COVID-19.

Thumbnail

COVID-19 caused CVD deaths in the U.S. to spike, new research confirms

Researchers explored updated data from the AHA, noting that the number of CVD-related deaths increased from more than 874,000 in 2019 to more than 928,000 in 2020.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup